

Request under Freedom of Information Act 2000

Request Ref: NGFOI 19/20: 095

Thank you for your request for information received at Northampton General Hospital NHS Trust (NGH) on 21/05/2019.

I am pleased to be able to provide you with the following information:

1 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Non-small cell Lung Cancer (NSCLC) with the following:

Paclitaxel	0
Gemcitabine	0
Osimertinib	<5
Carboplatin and Pemetrexed	11
Cisplatin and Pemetrexed	6
Pembrolizumab monotherapy	<5
Pembrolizumab in combination	16
Atezolizumab	6
Nivolumab	<5
Other active systemic anti-cancer therapy	0

2a – Does your Health Trust participate in any ongoing clinical trails for the treatment of Metastatic Non Small Cell Lung cancer patients?

No

2b – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials?

N/A

3 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Colorectal Cancer (CRC) with the following:

Cetuximab not in combination with FOLFIRIE or FOLOX	15
Cetuximab in combination with FOLFIRI	0
Cetuximab in combination with FOLFOX	0
Panitumumab not in combination with FOLFIRI or FOLFOX	5
Panitumumab in combination with FOLFIRI	0
Panitumumab in combination with FOLFOX	0
Nivolumab	<5







Aflibercept	0
Bevacizumab	0
Ramucirumab	0
Regorafenib	0
Sorafenib	0

Other active systemic anti-cancer therapy (eg 5FU, CAPIRI, CAPOX, FOLFIRI, FOLFOX, Oxaliplatin, Irinotecan, Tegafur or Uracil + 5FU)

119

3a – Does your Health Trust participate in any ongoing clinical trials for the treatment of Colorectal cancer patients?

Yes

3b – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials?

FOCUS4 – 19 patients ADD-ASPIRIN colorectal cohort – 38 patients

4 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Head and Neck Cancer (Squamous Cell Carcinoma)?

77

4a – If your Trust is able to split these patients, how many are locally advanced and how many are recurrent and or metastatic Head and Neck Cancer patients?

Locally advanced

Recurrent metastatic

Unable to split

4b – Of the Head and Neck cancer patients please split by their current drug treatment (if you are unable to split by locally advanced and recurrent please state the total)

Carboplatin (only or in combination with 5-FU)	0
Cisplatin (only or in combination with 5-FU)	0
Cetuximab with / without chemotherapy	<5
Cetuximab with radiotherapy	0
Pembrolizumab monotherapy	0
Pembrolizumab with chemotherapy	0
Nivolumab	<5
Docetaxel (only or in combination with 5-FU)	0
Fluorouracil (5-FU)	0
Radiotherapy only	32







Other 35

4c – Does your Health Trust participate in any ongoing clinical trials for the treatment of Head and Neck cancer patients?

Yes

4d – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials?

DE-ESCALATE (clinical trial for Head & Neck squamous cell carcinoma) - <5 patients

5 – Within your Health Trust how many patients are currently (within the past 6 months available) being treated for Urothelial Carcinoma UCC) with the following:

Cisplatin single agent	0
Cisplatin in combination with another agent	10
Carboplatin single agent	0
Carboplatin in combination with another agent	<5
Nivolumab	0
Pembrolizumab	<5
Atezolizumab	<5
Other active systemic anti-cancer therapy	0

5a – Does your Health Trust participate in any ongoing clinical trials for the treatment of Metastatic Urothelial Carcinoma patients?

No

5b – If so how many patients are currently taking part in clinical trials / what is the name(s) of the trials?

N/A

Please note that, in accordance with the Freedom of Information Act, Exemption section 40 (Personal Information) has been applied where the number of patients is less than 5. Due to the low numbers involved we have withheld the exact numbers to protect the identities of individuals.

While the Trust acknowledges that it is desirable to make information as freely available as possible the release of this information would be unfair to the individuals concerned and would contravene the rights of the individual under the Data Protection Act.

The information requested is therefore held exempt from disclosure under section 40 (Personal Information) of the Freedom of Information Act.



